Combined carboplatin and paclitaxel therapy improves overall survival in patients with nivolumab-resistant acral and mucosal melanoma

Br J Dermatol. 2021 Sep 12. doi: 10.1111/bjd.20758. Online ahead of print.ABSTRACTImmuno-oncology (IO) drugs are an essential treatment option for BRAF wild-type melanoma. However, effective treatment for IO drug-resistant BRAF wild-type melanoma is yet to be established. The proportion of BRAF wild-type melanoma is known to be higher in acral lentiginous melanoma (ALM) and mucosal melanoma (MCM) than in other clinical subtypes.1 Consequently, treatment options other than IO drugs have important implications for these clinical subtypes. Several studies have reported that the response rate (RR) of chemotherapy increases after IO drugs administration;2-4 however, no study has reported an improvement in survival analysis.PMID:34510408 | DOI:10.1111/bjd.20758
Source: The British Journal of Dermatology - Category: Dermatology Authors: Source Type: research